LEXINGTON, Mass.--(BUSINESS WIRE)--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that it is — for the third year in a row — teaming up with the New England Patriots Radio Network, 98.5 The Sports Hub, and its 36-station radio network throughout New England, during the 2011 New England Patriots season to recognize innovative science teachers in middle schools and high schools throughout New England.
During the season, Cubist and the New England Patriots Radio Network will recognize science teachers leading the way in the classroom. Each week, during the New England Patriots season, a teacher will be selected as the Cubist Pharmaceuticals “Teacher of the Week” and announced during the New England Patriots radio broadcast. Each teacher selected will be qualified to be recognized as the recipient of the Cubist Pharmaceuticals Science Education Leadership Award. The grand prize winning teacher will have a special meet and greet with Patriots broadcasters at the CBS Scene in Foxboro at the last home game of the 2011 season on January 1, 2012. Cubist will also present a $5000 check to the winning teacher’s school science program, and a Patriots alumni player will be making a special appearance at that teacher’s school at the end of the season. Log onto the patriotsradionetwork.com to enter online.
Cubist President and CEO Michael Bonney said, “Cubist is committed, both through its philanthropic efforts and by encouraging our employees to volunteer in the community, to ensuring that today’s young people are prepared for careers in science if that is their desire. Critical to that preparation are the dedicated science teachers who are implementing innovative teaching techniques and opening young minds to the endless possibilities that science provides.”
Lance Hartford, Executive Director of the Massachusetts Biotechnology Education Foundation, said, “It is clear that effective science teaching and learning requires an integration of science fundamentals with real world applications. Cubist Pharmaceuticals is committed to providing teachers and students an understanding of how classroom science can be linked to science that meets critical patient needs. Cubist Pharmaceuticals’ Science Education Leadership Award is another example of how Cubist is supporting innovative approaches to teaching science. Congratulations to Cubist and to the teachers who work so hard to provide students new opportunities to explore the wonders of science.
About Cubist
Cubist Pharmaceuticals, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of pharmaceutical products that address significant unmet medical needs in the acute care environment. In the U.S., Cubist markets CUBICIN® (daptomycin for injection), the first antibiotic in a class of anti-infectives called lipopeptides, and has an agreement with Optimer Pharmaceuticals, Inc. to co-promote DIFICID™ in the U.S. as a treatment of CDAD (Clostridium difficile-associated diarrhea) in adults. The current Cubist clinical development pipeline includes CXA-201, a novel cephalosporin in combination with tazobactam in development for the treatment of certain serious infections caused by multi-drug resistant (MDR) Gram-negative organisms. CXA-201 is in Phase 3 trials for complicated urinary tract infections (cUTI), and Cubist expects to initiate Phase 3 trials with CXA-201 in complicated intra-abdominal infections (cIAI) by the end of 2011. In addition, Phase 3 trials of CXA-201 in hospital acquired (nosocomial) pneumonia are expected to begin in 2012. Cubist has completed Phase 2 trials of a novel antibacterial candidate, CB-183,315, for the treatment of CDAD and plans to make a go/no go decision of whether to move CB-183,315 into Phase 3 trials in the third quarter of 2011. Cubist also is working on several pre-clinical programs being developed to address areas of significant medical needs. These include therapies to treat various serious bacterial infections and acute pain. Cubist is headquartered in Lexington, Mass. Additional information can be found at Cubist’s web site at www.cubist.com.
Cubist and CUBICIN are registered trademarks of Cubist Pharmaceuticals, Inc.
DIFICID is a trademark of Optimer Pharmaceuticals, Inc.